Universal Diagnostics is a biomedicine start-up focused on the development of leading edge technologies in metabolomics, genetics and bioinformatics, with the mission to develop a blood test for early detection.
Välj den region som bäst passar din plats eller dina preferenser.
Denna inställning styr språket för användargränssnittet, inklusive knappar, menyer och all text på webbplatsen. Välj ditt föredragna språk för bästa surfupplevelse.
Välj de språk för jobbannonser du vill se. Denna inställning avgör vilka jobbannonser som visas för dig.
Universal Diagnostics is a biomedicine start-up focused on the development of leading edge technologies in metabolomics, genetics and bioinformatics, with the mission to develop a blood test for early detection.
The seed of Universal Diagnostics (UDX) was born at NASA Ames Park, in Mountain View, California, during the summer of 2012. Following SingularityUniversity’s global challenge to impact positively one billion people, two experienced technology entrepreneurs decided to launch together a bio-medicine start-up with the goal of fighting Humanity’s most important enemy: cancer.
The company was officially incorporated in Spain.
The monumental goal of UDX is to develop a test to detect cancer early, when it still can be cured and save millions of lives.
The company closed a seed round of capital from international investors.
UDX started a large-scale research metabolomics project for discovering ex-novo biomarkers for different cancers with high incidence and mortality rate in the world.
UDX has established alliances and collaborations with international universities, companies, biobanks and hospitals to validate the technology in all races and populations.
Following clinical trials and regulatory approval, UDX will offer tests for the early diagnostics of the most prevalent cancers.
UDX’s first product is a blood-based test for the early detection of colorectal cancer and polyps, the precursor to colorectal cancer.